Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems
Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Diabetes technology & therapeutics - 26(2024), 4 vom: 26. Apr., Seite 263-275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eichenlaub, Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood Glucose |
|---|
| Anmerkungen: |
Date Completed 05.04.2024 Date Revised 05.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1089/dia.2023.0465 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366848267 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366848267 | ||
| 003 | DE-627 | ||
| 005 | 20240405233352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/dia.2023.0465 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM366848267 | ||
| 035 | |a (NLM)38194227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eichenlaub, Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring Systems |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to the lack of comprehensive guidelines for clinical study design. In particular, the absence of concise requirements for the distribution of comparator (reference) blood glucose (BG) concentrations and their rate of change (RoC) that are used to evaluate CGM performance, impairs comparability. For this article, several experts in the field of CGM performance testing have collaborated to propose characteristics of the distribution of comparator measurements that should be collected during CGM performance testing. Specifically, it is proposed that at least 7.5% of comparator BG concentrations are <70 mg/dL (3.9 mmol/L) and >300 mg/dL (16.7 mmol/L), respectively, and that at least 7.5% of BG-RoC combinations indicate fast BG changes with impending hypo- or hyperglycemia, respectively. These proposed characteristics of the comparator data can facilitate the harmonization of testing conditions across different studies and CGM systems and ensure that the most relevant scenarios representing real-life situations are established during performance testing. In addition, a study protocol and testing procedure for the manipulation of glucose levels are suggested that enable the collection of comparator data with these characteristics. This work is an important step toward establishing a future standard for the performance evaluation of CGM systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical performance evaluation | |
| 650 | 4 | |a Comparator data characteristics | |
| 650 | 4 | |a Continuous glucose monitoring | |
| 650 | 4 | |a Glucose rate of change | |
| 650 | 4 | |a Standardization | |
| 650 | 4 | |a Testing procedures | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 700 | 1 | |a Pleus, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Rothenbühler, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Timothy S |e verfasserin |4 aut | |
| 700 | 1 | |a Bally, Lia |e verfasserin |4 aut | |
| 700 | 1 | |a Brazg, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Bruttomesso, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Diem, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson Boija, Elisabet |e verfasserin |4 aut | |
| 700 | 1 | |a Fokkert, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Haug, Cornelia |e verfasserin |4 aut | |
| 700 | 1 | |a Hinzmann, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Jendle, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Klonoff, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Mader, Julia K |e verfasserin |4 aut | |
| 700 | 1 | |a Makris, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Moser, Othmar |e verfasserin |4 aut | |
| 700 | 1 | |a Nichols, James H |e verfasserin |4 aut | |
| 700 | 1 | |a Nørgaard, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Pemberton, John |e verfasserin |4 aut | |
| 700 | 1 | |a Selvin, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Spanou, Loukia |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Nam K |e verfasserin |4 aut | |
| 700 | 1 | |a Witthauer, Lilian |e verfasserin |4 aut | |
| 700 | 1 | |a Slingerland, Robbert J |e verfasserin |4 aut | |
| 700 | 1 | |a Freckmann, Guido |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes technology & therapeutics |d 1999 |g 26(2024), 4 vom: 26. Apr., Seite 263-275 |w (DE-627)NLM113690495 |x 1557-8593 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2024 |g number:4 |g day:26 |g month:04 |g pages:263-275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/dia.2023.0465 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2024 |e 4 |b 26 |c 04 |h 263-275 | ||